Vitalgen
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Vitalgen - overview
Established
2020
Location
Shanghai, -, China
Primary Industry
Biotechnology
About
Founded in 2020 and based in Shanghai, China, Shanghai Vitalgen BioPharma Co. , Ltd. , trading as Vitalgen, specializes in pioneering gene therapy solutions. In September 2025, the firm closed a round of venture funding from Cinda Capital, Maotian Capital, and Shanghai Xuhui Venture Capital.
Vitalgen develops advanced gene delivery and editing technologies aimed at treating various genetic and neurodegenerative disorders. Its core products include ViVec® AAV vector technology, ViLNP® lipid nanoparticle technology, and ViCas® CRISPR gene editing technology. The company is actively advancing multiple products into clinical research, targeting global markets for diseases such as AADC deficiency and amyotrophic lateral sclerosis (ALS). The company generates revenue from partnerships and collaborations with biopharmaceutical companies, alongside direct sales of its gene therapy products.
The company plans to launch additional innovative gene therapies and aims to penetrate broader geographic regions beyond China, enhancing its global reach in the gene therapy sector.
Current Investors
IDG Capital, Apricot Capital, Jiupai Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Biotechnology, Pharmaceutical Research & Development, Specialty Pharmaceuticals
Website
www.vitalgen.com/
Verticals
HealthTech
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.